Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell
• Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
Iterum Therapeutics’s Earnings: A Preview
Iterum Therapeutics (NASDAQ:ITRM) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here’s what investors…
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers KalVista Pharma (NASDAQ:KALV) stock moved upwards by 31.5% to $21.1 during Tuesday’s pre-market session. The market value…
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers SINTX Techs (NASDAQ:SINT) shares increased by 75.0% to $0.41 during Tuesday’s after-market session. The market value of…
Why Iterum Therapeutics Stock Is Trending Today
Iterum Therapeutics announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Agape ATP (NASDAQ:ATPC) shares rose 92.1% to $0.98 during Tuesday’s pre-market session. The company’s market cap stands…
Insiders Buying Iterum Therapeutics And 3 Other Stocks Under $3
The Dow Jones index closed higher by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 62.0% to $1.62 during Tuesday’s regular session. The market value…
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers LumiraDx (NASDAQ:LMDX) shares rose 42.8% to $0.14 during Thursday’s regular session. LumiraDx’s stock is trading at a…
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell
• CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.